JP5669729B2 - 代謝性障害を治療するのに有用なサリチレートコンジュゲート - Google Patents
代謝性障害を治療するのに有用なサリチレートコンジュゲート Download PDFInfo
- Publication number
- JP5669729B2 JP5669729B2 JP2011508909A JP2011508909A JP5669729B2 JP 5669729 B2 JP5669729 B2 JP 5669729B2 JP 2011508909 A JP2011508909 A JP 2011508909A JP 2011508909 A JP2011508909 A JP 2011508909A JP 5669729 B2 JP5669729 B2 JP 5669729B2
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- hydrogen
- patient
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000030159 metabolic disease Diseases 0.000 title claims description 70
- 229960001860 salicylate Drugs 0.000 title description 10
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 title description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 448
- 239000001257 hydrogen Substances 0.000 claims description 448
- 150000001875 compounds Chemical class 0.000 claims description 399
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 327
- 238000011282 treatment Methods 0.000 claims description 223
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 201
- 150000003839 salts Chemical class 0.000 claims description 158
- -1 ethoxy, methoxy Chemical group 0.000 claims description 123
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims description 116
- 206010012601 diabetes mellitus Diseases 0.000 claims description 112
- 201000001421 hyperglycemia Diseases 0.000 claims description 111
- 239000003814 drug Substances 0.000 claims description 109
- 239000003937 drug carrier Substances 0.000 claims description 106
- 206010022489 Insulin Resistance Diseases 0.000 claims description 104
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 100
- 230000003820 β-cell dysfunction Effects 0.000 claims description 99
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 95
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 95
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 94
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 94
- 239000008194 pharmaceutical composition Substances 0.000 claims description 94
- 238000004519 manufacturing process Methods 0.000 claims description 92
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 83
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 67
- 229960004308 acetylcysteine Drugs 0.000 claims description 61
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 43
- 239000000203 mixture Substances 0.000 claims description 31
- 150000003626 triacylglycerols Chemical class 0.000 claims description 19
- KFPSMLWCEKSFGQ-SFHVURJKSA-N (2r)-2-acetamido-3-[5-acetyloxy-2-(2,4-difluorophenyl)benzoyl]sulfanylpropanoic acid Chemical compound CC(=O)N[C@H](C(O)=O)CSC(=O)C1=CC(OC(C)=O)=CC=C1C1=CC=C(F)C=C1F KFPSMLWCEKSFGQ-SFHVURJKSA-N 0.000 claims description 5
- PIWCGLSRQOXSTM-INIZCTEOSA-N (2r)-2-acetamido-3-[2-(2,4-difluorophenyl)-5-hydroxybenzoyl]sulfanylpropanoic acid Chemical compound CC(=O)N[C@H](C(O)=O)CSC(=O)C1=CC(O)=CC=C1C1=CC=C(F)C=C1F PIWCGLSRQOXSTM-INIZCTEOSA-N 0.000 claims description 4
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 8
- 206010014486 Elevated triglycerides Diseases 0.000 claims 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 description 327
- 241000124008 Mammalia Species 0.000 description 144
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 141
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 133
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 131
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 description 128
- 150000002431 hydrogen Chemical class 0.000 description 115
- 238000002360 preparation method Methods 0.000 description 100
- 230000003859 lipid peroxidation Effects 0.000 description 95
- 229910052736 halogen Inorganic materials 0.000 description 91
- 230000003647 oxidation Effects 0.000 description 90
- 238000007254 oxidation reaction Methods 0.000 description 90
- 102000007330 LDL Lipoproteins Human genes 0.000 description 89
- 108010007622 LDL Lipoproteins Proteins 0.000 description 89
- 150000002367 halogens Chemical class 0.000 description 88
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 76
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 description 50
- 201000001320 Atherosclerosis Diseases 0.000 description 49
- 208000027866 inflammatory disease Diseases 0.000 description 49
- 208000024172 Cardiovascular disease Diseases 0.000 description 48
- 208000017442 Retinal disease Diseases 0.000 description 48
- 206010038923 Retinopathy Diseases 0.000 description 48
- 208000017169 kidney disease Diseases 0.000 description 48
- 201000001119 neuropathy Diseases 0.000 description 48
- 230000007823 neuropathy Effects 0.000 description 48
- 208000033808 peripheral neuropathy Diseases 0.000 description 48
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 44
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 description 38
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 38
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 37
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 description 36
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 description 30
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 22
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 22
- 241000699670 Mus sp. Species 0.000 description 21
- 125000005138 alkoxysulfonyl group Chemical group 0.000 description 21
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 21
- 239000008103 glucose Substances 0.000 description 21
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 20
- 125000005843 halogen group Chemical group 0.000 description 19
- 239000003963 antioxidant agent Substances 0.000 description 18
- 230000000694 effects Effects 0.000 description 18
- 230000008569 process Effects 0.000 description 18
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 17
- 239000008280 blood Substances 0.000 description 17
- 210000004369 blood Anatomy 0.000 description 17
- 235000021588 free fatty acids Nutrition 0.000 description 17
- 241001465754 Metazoa Species 0.000 description 16
- 229940079593 drug Drugs 0.000 description 16
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 16
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- JVJFIQYAHPMBBX-UHFFFAOYSA-N 4-hydroxynonenal Chemical compound CCCCCC(O)C=CC=O JVJFIQYAHPMBBX-UHFFFAOYSA-N 0.000 description 14
- 235000006708 antioxidants Nutrition 0.000 description 14
- 230000002757 inflammatory effect Effects 0.000 description 14
- 230000003078 antioxidant effect Effects 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- 125000000217 alkyl group Chemical group 0.000 description 12
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 12
- 102000004877 Insulin Human genes 0.000 description 11
- 108090001061 Insulin Proteins 0.000 description 11
- 229940125396 insulin Drugs 0.000 description 11
- 230000036542 oxidative stress Effects 0.000 description 11
- 239000003642 reactive oxygen metabolite Substances 0.000 description 11
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 10
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 10
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 10
- 241000700159 Rattus Species 0.000 description 10
- SZERUUDEGZNTMV-UHFFFAOYSA-N [2-[[3,5-bis(trifluoromethyl)phenyl]carbamoyl]-4-chlorophenyl] acetate Chemical compound CC(=O)OC1=CC=C(Cl)C=C1C(=O)NC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 SZERUUDEGZNTMV-UHFFFAOYSA-N 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 229960003180 glutathione Drugs 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 229910052717 sulfur Inorganic materials 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 9
- 239000007795 chemical reaction product Substances 0.000 description 9
- 229910052760 oxygen Inorganic materials 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 208000002193 Pain Diseases 0.000 description 8
- 230000001684 chronic effect Effects 0.000 description 8
- 230000036252 glycation Effects 0.000 description 8
- 239000002502 liposome Substances 0.000 description 8
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 229960004889 salicylic acid Drugs 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 238000007912 intraperitoneal administration Methods 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 6
- 201000004624 Dermatitis Diseases 0.000 description 6
- 108010024636 Glutathione Proteins 0.000 description 6
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- CHILCFMQWMQVAL-UHFFFAOYSA-N N-[3,5-bis(trifluoromethyl)phenyl]-5-chloro-2-hydroxybenzamide Chemical compound OC1=CC=C(Cl)C=C1C(=O)NC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 CHILCFMQWMQVAL-UHFFFAOYSA-N 0.000 description 6
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 231100000252 nontoxic Toxicity 0.000 description 6
- 230000003000 nontoxic effect Effects 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 6
- 229960001052 streptozocin Drugs 0.000 description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 5
- 0 CC(NC(CS)C(IC)=O)=* Chemical compound CC(NC(CS)C(IC)=O)=* 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 206010037660 Pyrexia Diseases 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 230000008878 coupling Effects 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 238000007446 glucose tolerance test Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 229940090044 injection Drugs 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 239000006187 pill Substances 0.000 description 5
- 239000007909 solid dosage form Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 239000001993 wax Substances 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 4
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 4
- 206010009900 Colitis ulcerative Diseases 0.000 description 4
- 208000019693 Lung disease Diseases 0.000 description 4
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 201000006704 Ulcerative Colitis Diseases 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- 230000003178 anti-diabetic effect Effects 0.000 description 4
- 208000010668 atopic eczema Diseases 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 239000012320 chlorinating reagent Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 239000003701 inert diluent Substances 0.000 description 4
- 239000007928 intraperitoneal injection Substances 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 229940118019 malondialdehyde Drugs 0.000 description 4
- 210000003470 mitochondria Anatomy 0.000 description 4
- 201000008482 osteoarthritis Diseases 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- 208000019553 vascular disease Diseases 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- XMLFPUBZFSJWCN-UHFFFAOYSA-N 2-Hydroxy-4-trifluoromethyl benzoic acid Chemical compound OC(=O)C1=CC=C(C(F)(F)F)C=C1O XMLFPUBZFSJWCN-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UHFFFAOYSA-N 2-{[3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound OCC1OC(CO)(OC2OC(CO)C(O)C(O)C2O)C(O)C1O CZMRCDWAGMRECN-UHFFFAOYSA-N 0.000 description 3
- HCAJQHYUCKICQH-VPENINKCSA-N 8-Oxo-7,8-dihydro-2'-deoxyguanosine Chemical compound C1=2NC(N)=NC(=O)C=2NC(=O)N1[C@H]1C[C@H](O)[C@@H](CO)O1 HCAJQHYUCKICQH-VPENINKCSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 241000416162 Astragalus gummifer Species 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 206010017788 Gastric haemorrhage Diseases 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 208000019695 Migraine disease Diseases 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 208000012322 Raynaud phenomenon Diseases 0.000 description 3
- 206010040047 Sepsis Diseases 0.000 description 3
- 206010040070 Septic Shock Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 102000019197 Superoxide Dismutase Human genes 0.000 description 3
- 108010012715 Superoxide dismutase Proteins 0.000 description 3
- 208000009205 Tinnitus Diseases 0.000 description 3
- 229920001615 Tragacanth Polymers 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 235000010419 agar Nutrition 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 description 3
- 239000002260 anti-inflammatory agent Substances 0.000 description 3
- 239000000440 bentonite Substances 0.000 description 3
- 229910000278 bentonite Inorganic materials 0.000 description 3
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 3
- 230000036983 biotransformation Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 231100000762 chronic effect Toxicity 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 229940014259 gelatin Drugs 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000003914 insulin secretion Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 206010027599 migraine Diseases 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 229960004063 propylene glycol Drugs 0.000 description 3
- 239000007845 reactive nitrogen species Substances 0.000 description 3
- 230000036303 septic shock Effects 0.000 description 3
- 239000008247 solid mixture Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229960002663 thioctic acid Drugs 0.000 description 3
- 231100000886 tinnitus Toxicity 0.000 description 3
- 235000010487 tragacanth Nutrition 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- VYPKEODFNOEZGS-VIFPVBQESA-N (2r)-2-acetamido-3-(2-hydroxybenzoyl)sulfanylpropanoic acid Chemical compound CC(=O)N[C@H](C(O)=O)CSC(=O)C1=CC=CC=C1O VYPKEODFNOEZGS-VIFPVBQESA-N 0.000 description 2
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 2
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- KLDLRDSRCMJKGM-UHFFFAOYSA-N 3-[chloro-(2-oxo-1,3-oxazolidin-3-yl)phosphoryl]-1,3-oxazolidin-2-one Chemical compound C1COC(=O)N1P(=O)(Cl)N1CCOC1=O KLDLRDSRCMJKGM-UHFFFAOYSA-N 0.000 description 2
- HJBLUNHMOKFZQX-UHFFFAOYSA-N 3-hydroxy-1,2,3-benzotriazin-4-one Chemical compound C1=CC=C2C(=O)N(O)N=NC2=C1 HJBLUNHMOKFZQX-UHFFFAOYSA-N 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 208000004300 Atrophic Gastritis Diseases 0.000 description 2
- 208000031729 Bacteremia Diseases 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 208000020084 Bone disease Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 108010053835 Catalase Proteins 0.000 description 2
- 102000016938 Catalase Human genes 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- 208000015943 Coeliac disease Diseases 0.000 description 2
- 206010010741 Conjunctivitis Diseases 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- 101100508533 Drosophila melanogaster IKKbeta gene Proteins 0.000 description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 208000027445 Farmer Lung Diseases 0.000 description 2
- 208000036495 Gastritis atrophic Diseases 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 2
- 206010018634 Gouty Arthritis Diseases 0.000 description 2
- 241000590002 Helicobacter pylori Species 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 206010065390 Inflammatory pain Diseases 0.000 description 2
- 208000032382 Ischaemic stroke Diseases 0.000 description 2
- 208000012659 Joint disease Diseases 0.000 description 2
- 201000009906 Meningitis Diseases 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 102000003945 NF-kappa B Human genes 0.000 description 2
- 108010057466 NF-kappa B Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010033645 Pancreatitis Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- 208000008469 Peptic Ulcer Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 2
- 208000003782 Raynaud disease Diseases 0.000 description 2
- 206010063837 Reperfusion injury Diseases 0.000 description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
- 241000220317 Rosa Species 0.000 description 2
- SKZKKFZAGNVIMN-UHFFFAOYSA-N Salicilamide Chemical compound NC(=O)C1=CC=CC=C1O SKZKKFZAGNVIMN-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 2
- 201000002661 Spondylitis Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 206010046851 Uveitis Diseases 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 208000005298 acute pain Diseases 0.000 description 2
- 230000010014 adipocyte dysfunction Effects 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000002917 arthritic effect Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000000923 atherogenic effect Effects 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 208000019664 bone resorption disease Diseases 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000023852 carbohydrate metabolic process Effects 0.000 description 2
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 239000002385 cottonseed oil Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 229960000616 diflunisal Drugs 0.000 description 2
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
- 229940093471 ethyl oleate Drugs 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 208000030533 eye disease Diseases 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- IXZISFNWUWKBOM-ARQDHWQXSA-N fructosamine Chemical compound NC[C@@]1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O IXZISFNWUWKBOM-ARQDHWQXSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 208000007565 gingivitis Diseases 0.000 description 2
- 229940037467 helicobacter pylori Drugs 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 208000009326 ileitis Diseases 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 201000011486 lichen planus Diseases 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 208000021722 neuropathic pain Diseases 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 239000003605 opacifier Substances 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 208000000689 peptic esophagitis Diseases 0.000 description 2
- 208000028169 periodontal disease Diseases 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 229960000953 salsalate Drugs 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 229960004025 sodium salicylate Drugs 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 239000003206 sterilizing agent Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- QLOBGRBOWVVKIE-NSHDSACASA-N (2r)-2-acetamido-3-(2-acetyloxybenzoyl)sulfanylpropanoic acid Chemical compound CC(=O)N[C@H](C(O)=O)CSC(=O)C1=CC=CC=C1OC(C)=O QLOBGRBOWVVKIE-NSHDSACASA-N 0.000 description 1
- GUDLYYWEHXOTLB-NSHDSACASA-N (2r)-2-acetamido-3-[2-acetyloxy-4-(trifluoromethyl)benzoyl]sulfanylpropanoic acid Chemical compound CC(=O)N[C@H](C(O)=O)CSC(=O)C1=CC=C(C(F)(F)F)C=C1OC(C)=O GUDLYYWEHXOTLB-NSHDSACASA-N 0.000 description 1
- ZQSXWZPXVSKJFE-VIFPVBQESA-N (2r)-2-acetamido-3-[2-hydroxy-4-(trifluoromethyl)benzoyl]sulfanylpropanoic acid Chemical compound CC(=O)N[C@H](C(O)=O)CSC(=O)C1=CC=C(C(F)(F)F)C=C1O ZQSXWZPXVSKJFE-VIFPVBQESA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- FIARMZDBEGVMLV-UHFFFAOYSA-N 1,1,2,2,2-pentafluoroethanolate Chemical group [O-]C(F)(F)C(F)(F)F FIARMZDBEGVMLV-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- 125000003562 2,2-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- LHXSNNQCOOMGSG-HNNXBMFYSA-N 2-[(2r)-2-acetamido-3-sulfanylpropanoyl]oxy-5-(2,4-difluorophenyl)benzoic acid Chemical compound C1=C(C(O)=O)C(OC(=O)[C@H](CS)NC(=O)C)=CC=C1C1=CC=C(F)C=C1F LHXSNNQCOOMGSG-HNNXBMFYSA-N 0.000 description 1
- ORNUHFLPVVDQMU-LLVKDONJSA-N 2-[5-[(3r)-dithiolan-3-yl]pentanoyloxy]benzoic acid Chemical compound OC(=O)C1=CC=CC=C1OC(=O)CCCC[C@H]1SSCC1 ORNUHFLPVVDQMU-LLVKDONJSA-N 0.000 description 1
- RMWVZGDJPAKBDE-UHFFFAOYSA-N 2-acetyloxy-4-(trifluoromethyl)benzoic acid Chemical compound CC(=O)OC1=CC(C(F)(F)F)=CC=C1C(O)=O RMWVZGDJPAKBDE-UHFFFAOYSA-N 0.000 description 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
- 125000003469 3-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- KADKGTMPVXTIED-OAHLLOKOSA-N 5-(2,4-difluorophenyl)-2-[5-[(3r)-dithiolan-3-yl]pentanoyloxy]benzoic acid Chemical compound OC(=O)C1=CC(C=2C(=CC(F)=CC=2)F)=CC=C1OC(=O)CCCC[C@@H]1CCSS1 KADKGTMPVXTIED-OAHLLOKOSA-N 0.000 description 1
- NNHMQZBVJPQCAK-UHFFFAOYSA-N 5-chloro-2-hydroxybenzamide Chemical compound NC(=O)C1=CC(Cl)=CC=C1O NNHMQZBVJPQCAK-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- JYONQRKWHNGNMV-PIJUOVFKSA-N CC(CN[C@H](CSC(C(CS)NC(C)=O)=O)/C(/C)=[O]/C)=O Chemical compound CC(CN[C@H](CSC(C(CS)NC(C)=O)=O)/C(/C)=[O]/C)=O JYONQRKWHNGNMV-PIJUOVFKSA-N 0.000 description 1
- NARVQLMWUVLMCT-HNNXBMFYSA-N CC(N[C@@H](CSC(c(cc(cc1)-c(c(F)c2)ccc2F)c1O)=O)C(O)=O)=O Chemical compound CC(N[C@@H](CSC(c(cc(cc1)-c(c(F)c2)ccc2F)c1O)=O)C(O)=O)=O NARVQLMWUVLMCT-HNNXBMFYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241001661501 Coruna Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- YVGGHNCTFXOJCH-UHFFFAOYSA-N DDT Chemical compound C1=CC(Cl)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(Cl)C=C1 YVGGHNCTFXOJCH-UHFFFAOYSA-N 0.000 description 1
- 208000037487 Endotoxemia Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 102000013266 Human Regular Insulin Human genes 0.000 description 1
- 108010090613 Human Regular Insulin Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 101710186643 Insulin-2 Proteins 0.000 description 1
- 102000003810 Interleukin-18 Human genes 0.000 description 1
- 108090000171 Interleukin-18 Proteins 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- GTGADWNGRLTPSO-SECBINFHSA-N O=C(CCCC[C@H]1SSCC1)CI Chemical compound O=C(CCCC[C@H]1SSCC1)CI GTGADWNGRLTPSO-SECBINFHSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 239000012317 TBTU Substances 0.000 description 1
- 102100036407 Thioredoxin Human genes 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 1
- WXIONIWNXBAHRU-UHFFFAOYSA-N [dimethylamino(triazolo[4,5-b]pyridin-3-yloxy)methylidene]-dimethylazanium Chemical compound C1=CN=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 WXIONIWNXBAHRU-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 150000001323 aldoses Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 125000005210 alkyl ammonium group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 150000001371 alpha-amino acids Chemical class 0.000 description 1
- 235000008206 alpha-amino acids Nutrition 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000001548 androgenic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- XMFCLBUQBWFZBP-UHFFFAOYSA-N bis(2-methylimidazol-1-yl)methanone Chemical compound CC1=NC=CN1C(=O)N1C(C)=NC=C1 XMFCLBUQBWFZBP-UHFFFAOYSA-N 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000005708 carbonyloxy group Chemical group [*:2]OC([*:1])=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 150000001767 cationic compounds Chemical class 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- RAFNCPHFRHZCPS-UHFFFAOYSA-N di(imidazol-1-yl)methanethione Chemical compound C1=CN=CN1C(=S)N1C=CN=C1 RAFNCPHFRHZCPS-UHFFFAOYSA-N 0.000 description 1
- 125000005131 dialkylammonium group Chemical group 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 229940093181 glucose injection Drugs 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229940103471 humulin Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000008798 inflammatory stress Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000006677 mitochondrial metabolism Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- IDVWLLCLTVBSCS-UHFFFAOYSA-N n,n'-ditert-butylmethanediimine Chemical compound CC(C)(C)N=C=NC(C)(C)C IDVWLLCLTVBSCS-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical group C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 150000005830 nonesterified fatty acids Chemical class 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 238000007410 oral glucose tolerance test Methods 0.000 description 1
- 229940041678 oral spray Drugs 0.000 description 1
- 239000000668 oral spray Substances 0.000 description 1
- 150000002892 organic cations Chemical class 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 210000002824 peroxisome Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- UFUASNAHBMBJIX-UHFFFAOYSA-N propan-1-one Chemical group CC[C]=O UFUASNAHBMBJIX-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 229960000581 salicylamide Drugs 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical compound [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005207 tetraalkylammonium group Chemical group 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 108060008226 thioredoxin Proteins 0.000 description 1
- 229940094937 thioredoxin Drugs 0.000 description 1
- 230000009092 tissue dysfunction Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 125000005208 trialkylammonium group Chemical group 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 229960002268 triflusal Drugs 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 238000011664 type 2 diabetes animal model Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Description
酸化的ストレスおよび炎症は、代謝性疾患、糖尿病、肥満、脂質異常症およびその関連心血管系合併症の発症に関与する。例えば、酸化的ストレスは、インスリン抵抗性、β細胞機能障害、耐糖能異常、および2型糖尿病をもたらす共通病原性因子である。炎症に関して、臨床研究は、急激な高血糖が循環炎症性サイトカイン、例えば、TNFα、IL6、およびIL18の濃度の上昇をもたらすことを示唆する。
本発明は、サリチル酸および抗酸化剤からなるコンジュゲートに関する。本発明のコンジュゲートは、アテローム性動脈硬化、ニューロパシー、腎症、網膜症、炎症性疾患、心血管疾患、および代謝性障害、例えば、I型およびII型糖尿病を含む任意の種類の糖尿病、メタボリック・シンドローム、高血糖、およびインスリン感受性を治療するのに有用である。コンジュゲートはまた、糖化最終産物(AGE)、ROS、脂質過酸化反応、組織および血漿TNFαおよびIL6レベルを低下させるのにならびにアテローム性動脈硬化に付随する心血管系合併症を遅延または阻害するのに有用である。また、本発明のコンジュゲートは、膵β細胞を保護し、その機能障害または障害およびその後のより低いインスリン分泌を阻害するのに有用である。特に、本発明は、本明細書に記載の障害を治療するための、サルナセジン、サリチル酸およびN−アセチルシステインのコンジュゲートの使用を例示している。
R1は、水素、(C1−C6)アルキルカルボニル、またはAであり;
R2、R3、R4、およびR5は、独立して、水素、(C1−C6)アルコキシ、(C1−C6)アルコキシカルボニル、(C1−C6)アルコキシスルホニル、(C1−C6)アルキル、(C1−C6)アルキルカルボニル、(C1−C6)アルキルカルボニルオキシ、(C1−C6)アルキルスルホニル、(C1−C6)アルキルチオ、カルボキシ、シアノ、ホルミル、ハロ、(C1−C6)アルコキシ、ハロ(C1−C6)アルキル、ハロゲン、ヒドロキシ、ヒドロキシ(C1−C6)アルキル、メルカプト、ニトロ、フェニル、−NZ1Z2、または(NZ1Z2)カルボニルであり、ここで、該フェニルは、独立して、(C1−C6)アルコキシ、(C1−C6)アルコキシカルボニル、(C1−C6)アルコキシスルホニル、(C1−C6)アルキル、(C1−C6)アルキルカルボニル、(C1−C6)アルキルカルボニルオキシ、(C1−C6)アルキルスルホニル、(C1−C6)アルキルチオ、カルボキシ、シアノ、ホルミル、ハロ(C1−C6)アルコキシ、ハロ(C1−C6)アルキル、ハロゲン、ヒドロキシ、ヒドロキシ(C1−C6)アルキル、メルカプト、ニトロ、フェニル、−NZ3Z4、(NZ3Z4)カルボニルである1、2、3、4、または5個の基で所望により置換されていもよく;
Z1、Z2、Z3、およびZ4は、独立して、水素、(C1−C6)アルキル、または(C1−C6)アルキルカルボニルであり;
R6は、−NZ5Z6、
Z5およびZ6は、独立して、水素、(C1−C6)アルキル、(C1−C6)アルキルカルボニル、フェニル、フェニル(CH2)−、またはフェニル(CH2)2−であり、ここで、該フェニルは、独立して、(C1−C6)アルコキシ、(C1−C6)アルコキシカルボニル、(C1−C6)アルコキシスルホニル、(C1−C6)アルキル、(C1−C6)アルキルカルボニル、(C1−C6)アルキルカルボニルオキシ、(C1−C6)アルキルスルホニル、(C1−C6)アルキルチオ、カルボキシ、シアノ、ホルミル、ハロ(C1−C6)アルコキシ、ハロ(C1−C6)アルキル、ハロゲン、ヒドロキシ、ヒドロキシ(C1−C6)アルキル、メルカプト、ニトロ、フェニル、−NZ7Z8、または(NZ7Z8)カルボニルである1、2、3、4、または5個の基で所望により置換されていてもよく;
Z7およびZ8は、独立して、水素、(C1−C6)アルキル、または(C1−C6)アルキルカルボニルであり;
R7は、(C1−C6)アルコキシ、(C1−C6)アルキル、(C1−C6)アルキルチオ、ヒドロキシ、または−NZ9Z10であり;
R8は、水素または(C1−C6)アルキルであり;
R9は、水素、(C1−C6)アルキル、または(C1−C6)アルキルカルボニルであり;
R10は、(C1−C6)アルコキシ、(C1−C6)アルキル、(C1−C6)アルキルチオ、ヒドロキシ、または−NZ9Z10であり;
Z9およびZ10は、独立して、水素、(C1−C6)アルキル、または(C1−C6)アルキルカルボニルであり;
X1およびX2は、独立して、OまたはSであり;
Lは、(C1−C6)アルキレンであり;
Aは、
R1aは、水素、(C1−C6)アルキルカルボニル、またはBであり;
R2a、R3a、R4a、およびR5aは、独立して、水素、(C1−C6)アルコキシ、(C1−C6)アルコキシカルボニル、(C1−C6)アルコキシスルホニル、(C1−C6)アルキル、(C1−C6)アルキルカルボニル、(C1−C6)アルキルカルボニルオキシ、(C1−C6)アルキルスルホニル、(C1−C6)アルキルチオ、カルボキシ、シアノ、ホルミル、ハロ(C1−C6)アルコキシ、ハロ(C1−C6)アルキル、ハロゲン、ヒドロキシ、ヒドロキシ(C1−C6)アルキル、メルカプト、ニトロ、フェニル、−NZ1aZ2a、または(NZ1aZ2a)カルボニルであり、ここで、該フェニルは、独立して、(C1−C6)アルコキシ、(C1−C6)アルコキシカルボニル、(C1−C6)アルコキシスルホニル、(C1−C6)アルキル、(C1−C6)アルキルカルボニル、(C1−C6)アルキルカルボニルオキシ、(C1−C6)アルキルスルホニル、(C1−C6)アルキルチオ、カルボキシ、シアノ、ホルミル、ハロ(C1−C6)アルコキシ、ハロ(C1−C6)アルキル、ハロゲン、ヒドロキシ、ヒドロキシ(C1−C6)アルキル、メルカプト、ニトロ、フェニル、−NZ3aZ4a、または(NZ3aZ4a)カルボニルである1、2、3、4、または5個の基で所望により置換されていてもよく;
Z1a、Z2a、Z3a、およびZ4aは、独立して、水素、(C1−C6)アルキル、または(C1−C6)アルキルカルボニルであり;
Bは、
R1bは、水素、(C1−C6)アルキルカルボニル、またはCであり;
R2b、R3b、R4b、およびR5bは、独立して、水素、(C1−C6)アルコキシ、(C1−C6)アルコキシカルボニル、(C1−C6)アルコキシスルホニル、(C1−C6)アルキル、(C1−C6)アルキルカルボニル、(C1−C6)アルキルカルボニルオキシ、(C1−C6)アルキルスルホニル、(C1−C6)アルキルチオ、カルボキシ、シアノ、ホルミル、ハロ(C1−C6)アルコキシ、ハロ(C1−C6)アルキル、ハロゲン、ヒドロキシ、ヒドロキシ(C1−C6)アルキル、メルカプト、ニトロ、フェニル、−NZ1bZ2b、または(NZ1bZ2b)カルボニルであり、ここで、該フェニルは、独立して、(C1−C6)アルコキシ、(C1−C6)アルコキシカルボニル、(C1−C6)アルコキシスルホニル、(C1−C6)アルキル、(C1−C6)アルキルカルボニル、(C1C6)アルキルカルボニルオキシ、(C1−C6)アルキルスルホニル、(C1−C6)アルキルチオ、カルボキシ、シアノ、ホルミル、ハロ(C1−C6)アルコキシ、ハロ(C1−C6)アルキル、ハロゲン、ヒドロキシ(C1−C6)アルキル、メルカプト、ニトロ、フェニル、−NZ3bZ4b、または(NZ3bZ4b)カルボニルである1、2、3、4、または5個の基で所望により置換されていてもよく;
Z1b、Z2b、Z3b、およびZ4bは、独立して、水素、(C1−C6)アルキル、または(C1−C6)アルキルカルボニルであり;および
Cは、
で示される化合物またはその医薬上許容される塩をかかる治療を必要とする哺乳動物または患者に投与する工程を含む方法を提供する。
本発明は、化合物、試薬、医薬組成物ならびに哺乳動物または患者のアテローム性動脈硬化、ニューロパシー、腎症、網膜症、炎症性疾患、心血管疾患、および代謝性障害の治療方法であって、治療上有効な量の式(I)の化合物(式中:R1は水素またはアセチルであり;R2、R3、R4、およびR5は、独立して、水素、トリフルオロメチル、または2,4−ジフルオロフェニルであり;R6は式(i)であり;ならびに、R7、R8、R9、X1、およびLは、概要セクションの式(I)の記載と同義である)またはその医薬上許容される塩をかかる治療を必要とする哺乳動物または患者に投与することを含む方法を提供する。
R1は、水素、(C1−C6)アルキルカルボニル、またはAであり;
R2、R3、R4、およびR5は、独立して、水素、(C1−C6)アルコキシ、(C1−C6)アルコキシカルボニル、(C1−C6)アルコキシスルホニル、(C1−C6)アルキル、(C1−C6)アルキルカルボニル、(C1−C6)アルキルカルボニルオキシ、(C1−C6)アルキルスルホニル、(C1−C6)アルキルチオ、カルボキシ、シアノ、ホルミル、ハロ(C1−C6)アルコキシ、ハロ(C1−C6)アルキル、ハロゲン、ヒドロキシ、ヒドロキシ(C1−C6)アルキル、メルカプト、ニトロ、フェニル、−NZ1Z2、または(NZ1Z2)カルボニルであり、ここで、該フェニルは、独立して、(C1−C6)アルコキシ、(C1−C6)アルコキシカルボニル、(C1−C6)アルコキシスルホニル、(C1−C6)アルキル、(C1−C6)アルキルカルボニル、(C1−C6)アルキルカルボニルオキシ、(C1−C6)アルキルスルホニル、(C1−C6)アルキルチオ、カルボキシ、シアノ、ホルミル、ハロ(C1−C6)アルコキシ、ハロ(C1−C6)アルキル、ハロゲン、ヒドロキシ、ヒドロキシ(C1−C6)アルキル、メルカプト、ニトロ、フェニル、−NZ3Z4、(NZ3Z4)カルボニルである1、2、3、4、または5個の基で所望により置換されていてもよく;
Z1、Z2、Z3、およびZ4は、独立して、水素、(C1−C6)アルキル、または(C1−C6)アルキルカルボニルであり;
R6は−NZ5Z6、
Z5およびZ6は、独立して、水素、(C1−C6)アルキル、(C1−C6)アルキルカルボニル、フェニル、フェニル(CH2)−、またはフェニル(CH2)2−であり、ここで、該フェニルは、独立して、(C1−C6)アルコキシ、(C1−C6)アルコキシカルボニル、(C1−C6)アルコキシスルホニル、(C1−C6)アルキル、(C1−C6)アルキルカルボニル、(C1−C6)アルキルカルボニルオキシ、(C1−C6)アルキルスルホニル、(C1−C6)アルキルチオ、カルボキシ、シアノ、ホルミル、ハロ(C1−C6)アルコキシ、ハロ(C1−C6)アルキル、ハロゲン、ヒドロキシ、ヒドロキシ(C1−C6)アルキル、メルカプト、ニトロ、フェニル、−NZ7Z8、または(NZ7Z8)カルボニルである1、2、3、4、または5個の基で所望により置換されていてもよく;
Z7およびZ8は、独立して、水素、(C1−C6)アルキル、または(C1−C6)アルキルカルボニルであり;
R7は、(C1−C6)アルコキシ、(C1−C6)アルキル、(C1−C6)アルキルチオ、ヒドロキシ、または−NZ9Z10であり;
R8は、水素または(C1−C6)アルキルであり;
R9は、水素、(C1−C6)アルキル、または(C1−C6)アルキルカルボニルであり;
R10は、(C1−C6)アルコキシ、(C1−C6)アルキル、(C1−C6)アルキルチオ、ヒドロキシ、または−NZ9Z10であり;
Z9およびZ10は、独立して、水素、(C1−C6)アルキル、または(C1−C6)アルキルカルボニルであり;
Aは、
R1aは、水素、(C1−C6)アルキルカルボニル、またはBであり;
R2a、R3a、R4a、およびR5aは、独立して、水素、(C1−C6)アルコキシ、(C1−C6)アルコキシカルボニル、(C1−C6)アルコキシスルホニル、(C1−C6)アルキル、(C1−C6)アルキルカルボニル、(C1−C6)アルキルカルボニルオキシ、(C1−C6)アルキルスルホニル、(C1−C6)アルキルチオ、カルボキシ、シアノ、ホルミル、ハロ(C1−C6)アルコキシ、ハロ(C1−C6)アルキル、ハロゲン、ヒドロキシ、ヒドロキシ(C1−C6)アルキル、メルカプト、ニトロ、フェニル、−NZ1aZ2a、または(NZ1aZ2a)カルボニルであり、ここで、該フェニルは、独立して、(C1−C6)アルコキシ、(C1−C6)アルコキシカルボニル、(C1−C6)アルコキシスルホニル、(C1−C6)アルキル、(C1−C6)アルキルカルボニル、(C1−C6)アルキルカルボニルオキシ、(C1−C6)アルキルスルホニル、(C1−C6)アルキルチオ、カルボキシ、シアノ、ホルミル、ハロ(C1−C6)アルコキシ、ハロ(C1−C6)アルキル、ハロゲン、ヒドロキシ、ヒドロキシ(C1−C6)アルキル、メルカプト、ニトロ、フェニル、−NZ3aZ4a、または(NZ3aZ4a)カルボニルである1、2、3、4、または5個の基で所望により置換されていてもよく;
Z1a、Z2a、Z3a、およびZ4aは、独立して、水素、(C1−C6)アルキル、または(C1−C6)アルキルカルボニルであり;
Bは、
R1bは、水素、(C1−C6)アルキルカルボニル、またはCであり;
R2b、R3b、R4b、およびR5bは、独立して、水素、(C1−C6)アルコキシ、(C1−C6)アルコキシカルボニル、(C1−C6)アルコキシスルホニル、(C1−C6)アルキル、(C1−C6)アルキルカルボニル、(C1−C6)アルキルカルボニルオキシ、(C1−C6)アルキルスルホニル、(C1−C6)アルキルチオ、カルボキシ、シアノ、ホルミル、ハロ(C1−C6)アルコキシ、ハロ(C1−C6)アルキル、ハロゲン、ヒドロキシ、ヒドロキシ(C1−C6)アルキル、メルカプト、ニトロ、フェニル、−NZ1bZ2b、または(NZ1bZ2b)カルボニルであり、ここで、該フェニルは、独立して、(C1−C6)アルコキシ、(C1−C6)アルコキシカルボニル、(C1−C6)アルコキシスルホニル、(C1−C6)アルキル、(C1−C6)アルキルカルボニル、(C1−C6)アルキルカルボニルオキシ、(C1−C6)アルキルスルホニル、(C1−C6)アルキルチオ、カルボキシ、シアノ、ホルミル、ハロ(C1−C6)アルコキシ、ハロ(C1−C6)アルキル、ハロゲン、ヒドロキシ、ヒドロキシ(C1−C6)アルキル、メルカプト、ニトロ、フェニル、−NZ3bZ4b、または(NZ3bZ4b)カルボニルである1、2、3、4、または5個の基で所望により置換されていてもよく;
Z1b、Z2b、Z3b、およびZ4bは、独立して、水素、(C1−C6)アルキル、または(C1−C6)アルキルカルボニルであり;および
Cは、
で示される化合物またはその医薬上許容される塩を提供する、ただし、式(I)は、R1が水素またはアセチルであり;R2、R3、およびR5が水素であり;R4がHまたは2,4−ジフルオロフェニルであり;およびR6が(L) N−アセチルシステイン、(D) N−アセチルシステイン、または(±) N−アセチルシステインである場合を包含しない。
で示される化合物を提供する。
で示される化合物を提供する。
R7は、(C1−C6)アルコキシ、(C1−C6)アルキル、(C1−C6)アルキルチオ、ヒドロキシ、または−NZ9Z10であり;
R8は、水素または(C1−C6)アルキルであり;
R9は、水素、(C1−C6)アルキル、または(C1−C6)アルキルカルボニルであり;
R10は、(C1−C6)アルコキシ、(C1−C6)アルキルチオ、ヒドロキシ、または−NZ9Z10であり;
X1およびX2は、独立して、OまたはSであり;
Lは(C1−C6)アルキレンであり;および
Z9およびZ10は、独立して、水素、(C1−C6)アルキル、または(C1−C6)アルキルカルボニルである]
で示される化合物を提供する。
R6は、
R7は、(C1−C6)アルコキシ、(C1−C6)アルキル、(C1−C6)アルキルチオ、ヒドロキシ、または−NZ9Z10であり;
R8は、水素または(C1−C6)アルキルであり;
R9は、水素、(C1−C6)アルキル、または(C1−C6)アルキルカルボニルであり;
R10は、(C1−C6)アルコキシ、(C1−C6)アルキルチオ、ヒドロキシ、または−NZ9Z10であり;
X1およびX2は、独立して、OまたはSであり;
Lは、(C1−C6)アルキレンであり;および
Z9およびZ10は、独立して、水素、(C1−C6)アルキル、または(C1−C6)アルキルカルボニルである]
で示される化合物を提供する。
R6は、
R7は、(C1−C6)アルコキシ、(C1−C6)アルキル、(C1−C6)アルキルチオ、ヒドロキシ、または−NZ9Z10であり;
R8は、水素または(C1−C6)アルキルであり;
R9は、水素、(C1−C6)アルキル、または(C1−C6)アルキルカルボニルであり;
R10は、(C1−C6)アルコキシ、(C1−C6)アルキルチオ、ヒドロキシ、または−NZ9Z10であり;
X1およびX2は、独立して、OまたはSであり;
Lは、(C1−C6)アルキレンであり;および
Z9およびZ10は、独立して、水素、(C1−C6)アルキル、または(C1−C6)アルキルカルボニルである]
で示される化合物を提供する。
本明細書および添付の特許請求の範囲に用いられる、以下の用語は、以下の意味を有する。
標題化合物は、EP 0 080 229に記載の製法と同様の製法を用いて調製される。
標題化合物は、EP 0 080 229に記載の製法と同様の製法を用いて調製される。
標題化合物は、EP 0 080 229に記載の製法と同様の製法を用いて調製される。
標題化合物は、EP 0 080 229に記載の製法と同様の製法を用いて調製される。
標題化合物は、BE 900328に記載の製法と同様の製法を用いて調製される。
標題化合物は、BE 900328に記載の製法と同様の製法を用いて調製される。
標題化合物は、BE 900328に記載の製法と同様の製法を用いて調製される。
標題化合物は、BE 900328に記載の製法と同様の製法を用いて調製される
。
ストレプトゾトシン処置ラットにおけるβ細胞欠乏の防御および高血糖の予防
ストレプトゾトシン投与によって作製された糖尿病マウスまたはラットは、対照と比べて脂質過酸化反応レベルの増大ならびに肝臓および腎臓の抗酸化酵素の活性の減少を示す。
ストレプトゾトシン暴露後の5日前およびその間、酸化的ストレスからβ細胞を保護し、対照に比べて時間とともに高血糖の発症を減少させる。
ストレプトゾトシン注射(120mg/kg腹腔内)によって誘発されるマウスは、250mg/kg/日(経口または腹腔内)の本発明の化合物、例えば、サルナセジンで4週間処置される。4週間の処置後、空腹時血糖、フルクトサミン、トリグリセリドおよびコレステロールを測定する。これらの生化学パラメーターは、対照群に比べて減少する。これらの血漿パラメーターの減少は、サリチレートまたは抗酸化剤単独(例えば、サリチレート単独またはN−アセチルシステイン単独)の処置で観察されるものより顕著である。
またさらに、炎症性サイトカイン、例えば、TNFαおよびIL−6、ならびに肝臓および腎臓のグルタチオン(GSH)レベルは、未処置動物に比べて減少する。
8週齢のob/obおよびdb/dbマウスは、強制経口投与によってまたは食物と合する薬剤と一緒にまたは皮下に250mg/kgの本発明の化合物、例えば、サルナセジンの日用量で3〜4週間処置される。4週間後、空腹時血糖値は、対照群に比べてまたはob/obおよびサリチレートまたは抗酸化剤単独(例えば、サリチル酸単独またはN−アセチルシステイン単独)で処置されたdb/dbマウスに比べて減少する。
抗酸化剤および炎症性物質を含むコンジュゲートがグルコース毒性およびβ細胞欠乏に付随する糖尿病の進行を徐々に阻害するか否かを評価するために、本発明者らは、サルナセジンを含む、式(I)の化合物が該2型糖尿病動物モデルの疾患の発症を改善するか否かを評価した。
動物.体重25〜30gの雄cd−1マウスを、Charles River Laboratories Spainから購入した。動物を、12時間の明/12時間の暗サイクルで22℃の動物施設に収容し、自由に食物を与えた。db/db変異を有する5週齢の雄マウスC57BL/Ks(The Jackson Laboratories)を、Charles River Laboratories Spain(Sant Cugat del Valles, Spain)から購入した。
β細胞破壊は、0.9%NaClに溶解された200mg/kgアロキサン(Sigma-Aldrich, San Luis, MO)の新たに調製された溶液の単回腹腔内注射によって3時間の絶食後にcd−1マウスにおいて誘導された。単回腹腔内薬物投与は、アロキサン投与の1時間前であった。PBS pH7.4に溶解された異なる薬物を投与された動物、および任意の薬物を投与されていない動物は、ビヒクル、本件では、PBS pH7.4を注射された。処置後、4日目に、動物を殺し、血漿を回収し、使用するまで−20℃で保存した。
動物を、1ヵ月間所定の薬物で処置した。投与経路は、単回腹腔内注射であった。血糖値を、体重測定としても、ラピッド・グルコース・アナライザー(Accu-Chek Aviva; Roche)を用いて1週間に3回、尾静脈からの血液中で測定した。食物および水摂取量を1週間に2回測定した。処置後、マウスを飼養状態においてCO2安楽死で殺し、血液を、抗凝固剤としてヘパリンを用いて、下大静脈(Inferior Cave Vein)から抽出し、血漿の調製まで4℃にて保持した。
3週間の処置で、飼養状態のマウスにインスリン耐性試験を行った。動物は、インスリン2UI/kg(Humulin(登録商標))の腹腔内注射を受けた。血糖値を、Tラピッド・グルコース・アナライザーを用いてインスリン注射後に、所定の時間に尾静脈からの血液中で測定した。
4週間の処置で、一晩の絶食後のマウスにブドウ糖負荷試験を行った。動物は、0.5g/kgグルコース(Glucosmon 50(登録商標))の腹腔内注射を受けた。血糖値を、ラピッド・グルコース・アナライザーを用いてグルコース注射後に、所定の時間に尾静脈からの血液中で測定した。
Claims (31)
- R1が、水素またはアセチルであり;
R 7が、エトキシ、メトキシ、またはヒドロキシであり;および
R 9が、アセチルである、請求項1記載の医薬組成物。 - R1が、水素またはアセチルであり;および
R 6が、(L) N−アセチルシステインである、請求項1記載の医薬組成物。 - 該化合物が、
(R)−2−アセトアミド−3−(2’,4’−ジフルオロ−4−ヒドロキシビフェニルカルボニルチオ)プロパン酸;
(R)−メチル 2−アセトアミド−3−(2’,4’−ジフルオロ−4−ヒドロキシビフェニルカルボニルチオ)プロパノアート;
(R)−エチル 2−アセトアミド−3−(2’,4’−ジフルオロ−4−ヒドロキシビフェニルカルボニルチオ)プロパノアート;
(R)−2−アセトアミド−3−(4−アセトキシ−2’,4’−ジフルオロビフェニルカルボニルチオ)プロパン酸;
(R)−メチル 2−アセトアミド−3−(4−アセトキシ−2’,4’−ジフルオロビフェニルカルボニルチオ)プロパノアート;または
(R)−エチル 2−アセトアミド−3−(4−アセトキシ−2’,4’−ジフルオロビフェニルカルボニルチオ)プロパノアート
またはその医薬上許容される塩から選択される、請求項1記載の医薬組成物。 - 該化合物が、(R)−2−アセトアミド−3−(2’,4’−ジフルオロ−4−ヒドロキシビフェニルカルボニルチオ)プロパン酸、またはその医薬上許容される塩である、請求項1記載の医薬組成物。
- 該化合物が、(R)−メチル 2−アセトアミド−3−(2’,4’−ジフルオロ−4−ヒドロキシビフェニルカルボニルチオ)プロパノアート、またはその医薬上許容される塩である、請求項1記載の医薬組成物。
- 該化合物が、(R)−エチル 2−アセトアミド−3−(2’,4’−ジフルオロ−4−ヒドロキシビフェニルカルボニルチオ)プロパノアート、またはその医薬上許容される塩である、請求項1記載の医薬組成物。
- 該化合物が、(R)−2−アセトアミド−3−(4−アセトキシ−2’,4’−ジフルオロビフェニルカルボニルチオ)プロパン酸、またはその医薬上許容される塩である、請求項1記載の医薬組成物。
- 該化合物が、(R)−メチル 2−アセトアミド−3−(4−アセトキシ−2’,4’−ジフルオロビフェニルカルボニルチオ)プロパノアート、またはその医薬上許容される塩である、請求項1記載の医薬組成物。
- 該化合物が、(R)−エチル 2−アセトアミド−3−(4−アセトキシ−2’,4’−ジフルオロビフェニルカルボニルチオ)プロパノアート、またはその医薬上許容される塩である、請求項1記載の医薬組成物。
- 代謝性障害がI型およびII型糖尿病を含む任意の種類の糖尿病である、請求項1〜10のいずれか一項に記載の医薬組成物。
- 代謝性障害がβ細胞機能障害である、請求項1〜10のいずれか一項に記載の医薬組成物。
- 代謝性障害がII型糖尿病である、請求項1〜10のいずれか一項に記載の医薬組成物。
- 代謝性障害が高血糖症である、請求項1〜10のいずれか一項に記載の医薬組成物。
- 代謝性障害がトリグリセリドの上昇である、請求項1〜10のいずれか一項に記載の医薬組成物。
- 代謝性障害がインスリン抵抗性である、請求項1〜10のいずれか一項に記載の医薬組成物。
- 代謝性障害がI型糖尿病である、請求項1〜10のいずれか一項に記載の医薬組成物。
- R1が、水素またはアセチルであり;
R 7が、エトキシ、メトキシ、またはヒドロキシであり;および
R 9が、アセチルである、請求項18記載の使用。 - R1が、水素またはアセチルであり;および
R 6が、(L) N−アセチルシステインである、請求項18記載の使用。 - 該化合物が、
(R)−2−アセトアミド−3−(2’,4’−ジフルオロ−4−ヒドロキシビフェニルカルボニルチオ)プロパン酸;
(R)−メチル 2−アセトアミド−3−(2’,4’−ジフルオロ−4−ヒドロキシビフェニルカルボニルチオ)プロパノアート;
(R)−エチル 2−アセトアミド−3−(2’,4’−ジフルオロ−4−ヒドロキシビフェニルカルボニルチオ)プロパノアート;
(R)−2−アセトアミド−3−(4−アセトキシ−2’,4’−ジフルオロビフェニルカルボニルチオ)プロパン酸;
(R)−メチル 2−アセトアミド−3−(4−アセトキシ−2’,4’−ジフルオロビフェニルカルボニルチオ)プロパノアート;または
(R)−エチル 2−アセトアミド−3−(4−アセトキシ−2’,4’−ジフルオロビフェニルカルボニルチオ)プロパノアート
またはその医薬上許容される塩から選択される、請求項18記載の使用。 - 該化合物が、(R)−2−アセトアミド−3−(2’,4’−ジフルオロ−4−ヒドロキシビフェニルカルボニルチオ)プロパン酸、またはその医薬上許容される塩である、請求項18記載の使用。
- 該化合物が、
(R)−メチル 2−アセトアミド−3−(2’,4’−ジフルオロ−4−ヒドロキシビフェニルカルボニルチオ)プロパノアートまたは
(R)−エチル 2−アセトアミド−3−(2’,4’−ジフルオロ−4−ヒドロキシビフェニルカルボニルチオ)プロパノアート
またはその医薬上許容される塩である、請求項18記載の使用。 - 該化合物が、
(R)−2−アセトアミド−3−(4−アセトキシ−2’,4’−ジフルオロビフェニルカルボニルチオ)プロパン酸;
(R)−メチル 2−アセトアミド−3−(4−アセトキシ−2’,4’−ジフルオロビフェニルカルボニルチオ)プロパノアート;または
(R)−エチル 2−アセトアミド−3−(4−アセトキシ−2’,4’−ジフルオロビフェニルカルボニルチオ)プロパノアート
またはその医薬上許容される塩である、請求項18記載の使用。 - 代謝性障害がI型およびII型糖尿病を含む任意の種類の糖尿病である、請求項18〜24のいずれか一項に記載の使用。
- 代謝性障害がβ細胞機能障害である、請求項18〜24のいずれか1項に記載の使用。
- 代謝性障害がII型糖尿病である、請求項18〜24のいずれか1項に記載の使用。
- 代謝性障害が高血糖症である、請求項18〜24のいずれか1項に記載の使用。
- 代謝性障害がトリグリセリドの上昇である、請求項18〜24のいずれか1項に記載の使用。
- 代謝性障害がインスリン抵抗性である、請求項18〜24のいずれか1項に記載の使用。
- 代謝性障害がI型糖尿病である、請求項18〜24のいずれか1項に記載の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5283908P | 2008-05-13 | 2008-05-13 | |
US61/052,839 | 2008-05-13 | ||
PCT/EP2009/055788 WO2009138437A1 (en) | 2008-05-13 | 2009-05-13 | Salicylate conjugates useful for treating metabolic disorders |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2011520836A JP2011520836A (ja) | 2011-07-21 |
JP2011520836A5 JP2011520836A5 (ja) | 2012-06-28 |
JP5669729B2 true JP5669729B2 (ja) | 2015-02-12 |
Family
ID=40827388
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011508909A Expired - Fee Related JP5669729B2 (ja) | 2008-05-13 | 2009-05-13 | 代謝性障害を治療するのに有用なサリチレートコンジュゲート |
Country Status (8)
Country | Link |
---|---|
US (2) | US20090298923A1 (ja) |
EP (1) | EP2291182A1 (ja) |
JP (1) | JP5669729B2 (ja) |
CN (2) | CN102088965B (ja) |
AU (1) | AU2009248057B2 (ja) |
BR (1) | BRPI0912716A2 (ja) |
CA (1) | CA2724023C (ja) |
WO (1) | WO2009138437A1 (ja) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2729186C (en) | 2008-07-08 | 2018-01-16 | Catabasis Pharmaceuticals, Inc. | Fatty acid acetylated salicylates and their uses |
US9085527B2 (en) | 2008-07-08 | 2015-07-21 | Catabasis Pharmaceuticals, Inc. | Fatty acid acylated salicylates and their uses |
CA2755069A1 (en) * | 2009-03-16 | 2010-09-23 | Genmedica Therapeutics Sl | Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders |
US8946451B2 (en) * | 2009-10-05 | 2015-02-03 | Catabasis Pharmaceuticals, Inc. | Lipoic acid acylated salicylate derivatives and their uses |
US8466197B2 (en) | 2010-12-14 | 2013-06-18 | Genmedica Therapeutics Sl | Thiocarbonates as anti-inflammatory and antioxidant compounds useful for treating metabolic disorders |
US8440723B2 (en) * | 2011-05-11 | 2013-05-14 | Banavara L. Mylari | Metformin salts of salicylic acid and its congeners |
US20150025006A1 (en) * | 2011-09-16 | 2015-01-22 | Genmedica Therapeutics Sl | Pharmaceutical Combinations Including Anti-Inflammatory and Antioxidant Conjugates Useful for Treating Metabolic Disorders |
WO2013037984A1 (en) * | 2011-09-16 | 2013-03-21 | Genmedica Therapeutics Sl | Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders |
KR20210091150A (ko) * | 2018-10-11 | 2021-07-21 | 바스프 에이에스 | 방향족 화합물 및 이의 약학적 용도 |
CN109761815A (zh) * | 2019-02-26 | 2019-05-17 | 首都医科大学附属北京天坛医院 | 一种基于白藜芦醇治疗神经系统疾病的化合物及制备方法 |
Family Cites Families (106)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1583602A (en) * | 1977-05-26 | 1981-01-28 | Sterwin Ag | N-acetyl-para-aminophenyl-n'-acetyl-amino-thioalkanoic acid ester derivatives |
IT1194117B (it) * | 1981-11-20 | 1988-09-14 | Isnardi Pietro & C Spa | Derivati salicilici di n-acetilcisteina |
IT1190987B (it) * | 1982-09-07 | 1988-02-24 | Pharma Edmond Srl | Tioesteri dell'acido acetilsalicilico,procedimento per la loro preparazione e composizioni farmaceutiche che li conttengono |
IT1206515B (it) * | 1983-08-09 | 1989-04-27 | Guidotti & C Spa Labor | N-acetilcisteina ederivati 2',4's-carbossimetilcisteina ad-difluoro-4-idrossi-(1,1'-bifenil)attivita' antinfiammatoria, 3-carbossilici della mucolitica, procedimento per laloro preparazione e relative composizioni farmaceutiche. |
US5948769A (en) * | 1984-01-28 | 1999-09-07 | Ismail; Roshdy | Agent for treating heart diseases |
EP0254032A3 (en) * | 1986-06-20 | 1990-09-05 | Schering Corporation | Neutral metalloendopeptidase inhibitors in the treatment of hypertension |
US5610180A (en) * | 1988-01-29 | 1997-03-11 | Virginia Commonwealth University | Ionizable congeners of aromatic and aliphatic alcohols as anti-leukemia agents |
JPH04217916A (ja) * | 1990-06-21 | 1992-08-07 | Japan Tobacco Inc | 抗炎症剤 |
US8178516B2 (en) * | 1992-06-30 | 2012-05-15 | Sylvan Labs, LLC | Compositions and method for treatment of chronic inflammatory diseases |
DE4444051A1 (de) * | 1994-12-10 | 1996-06-13 | Rhone Poulenc Rorer Gmbh | Pharmazeutische, oral anwendbare Zubereitung |
US5871769A (en) * | 1996-01-18 | 1999-02-16 | Fleming & Company, Pharmaceuticals | Methods and compositions for the prevention and treatment of diabetes mellitus |
KR20000035992A (ko) * | 1996-09-10 | 2000-06-26 | 메디녹스, 인크. | 폴리디티오카르바메이트 함유 거대분자 및 치료 및 진단을 위한 |
ITMI962356A1 (it) * | 1996-11-13 | 1998-05-13 | Uni Degli Studi Di Brescia D I | Uso di composti derivati da molecole ad attivita' antinfiammatoria di tipo non steroideo per la prevenzione e il trattamento di |
US6896899B2 (en) * | 1996-12-31 | 2005-05-24 | Antioxidant Pharmaceuticals Corp. | Pharmaceutical preparations of glutathione and methods of administration thereof |
PT1493439E (pt) * | 1997-04-02 | 2012-01-10 | Brigham & Womens Hospital | Meio de avaliação do perfil de risco de um indivíduo para uma doença aterosclerótica |
AU728488B2 (en) * | 1997-04-02 | 2001-01-11 | Sankyo Company Limited | Dithiolan derivatives, their preparation and their therapeutic effect |
AUPO612397A0 (en) * | 1997-04-11 | 1997-05-08 | University Of Queensland, The | Novel diflunisal esters and related compounds |
NZ528906A (en) * | 1997-05-14 | 2005-06-24 | Atherogenics Inc | Compounds and methods for the inhibition of the expression of VCAM-1 |
US6852878B2 (en) * | 1998-05-14 | 2005-02-08 | Atherogenics, Inc. | Thioketals and thioethers for inhibiting the expression of VCAM-1 |
US20020004515A1 (en) * | 1997-06-18 | 2002-01-10 | Smith Stephen Alistair | Treatment of diabetes with thiazolidinedione and metformin |
US5972986A (en) * | 1997-10-14 | 1999-10-26 | G.D. Searle & Co. | Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia |
US5905090A (en) * | 1998-04-29 | 1999-05-18 | Italfarmaco S.P.A. | Analogues of the active metabolite of leflunomide |
US6197340B1 (en) * | 1998-05-28 | 2001-03-06 | Medical Research Institute | Controlled release lipoic acid |
US6288234B1 (en) * | 1998-06-08 | 2001-09-11 | Advanced Medicine, Inc. | Multibinding inhibitors of microsomal triglyceride transferase protein |
US20020045580A1 (en) * | 1999-11-24 | 2002-04-18 | Sacks Meir S. | Compositions for raising uric acid levels and methods of using same |
AU5142699A (en) * | 1998-07-31 | 2000-02-28 | Mount Sinai Hospital Corporation | Methods and compositions for increasing insulin sensitivity |
WO2000015211A2 (en) * | 1998-09-17 | 2000-03-23 | Akesis Pharmaceuticals, Inc. | Compositions of chromium or vanadium with antidiabetics for glucose metabolism disorders |
US6201028B1 (en) * | 1998-12-08 | 2001-03-13 | The Rockefeller University | Methods and compositions for prevention and treatment of atherosclerosis and hyperlipidemia with non-steroidal anti-inflammatory drugs |
JP2007326864A (ja) * | 1999-01-20 | 2007-12-20 | Takara Bio Inc | 医薬組成物 |
CN1304008C (zh) * | 1999-01-20 | 2007-03-14 | 宝生物工程株式会社 | 医药组合物 |
IT1311924B1 (it) * | 1999-04-13 | 2002-03-20 | Nicox Sa | Composti farmaceutici. |
US20010051184A1 (en) * | 1999-05-20 | 2001-12-13 | Madalene C.Y. Heng | Method for using soluble curcumin to inhibit phosphorylase kinase in inflammatory diseases |
JP4618845B2 (ja) * | 1999-06-09 | 2011-01-26 | 杏林製薬株式会社 | ヒトペルオキシゾーム増殖薬活性化受容体(PPAR)αアゴニストとしての置換フェニルプロピオン酸誘導体 |
KR20020016833A (ko) * | 1999-06-15 | 2002-03-06 | 뉴트리-로직스, 인크. | 발병 감소에 유용한 영양 제제, 관련 치료 방법 및 성분스크리닝 방법 |
US6309663B1 (en) * | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
AU7995300A (en) * | 1999-10-05 | 2001-05-10 | Bethesda Pharmaceuticals, Inc. | Dithiolane derivatives |
US7323496B2 (en) * | 1999-11-08 | 2008-01-29 | Theracos, Inc. | Compounds for treatment of inflammation, diabetes and related disorders |
US20020155163A1 (en) * | 1999-12-27 | 2002-10-24 | Samuel D. Benjamin | Integrated multi-vitamin and mineral combination |
US20080044399A1 (en) * | 2000-04-20 | 2008-02-21 | Andrew Levy | Vitamin E supplementation for reducing cardiovascular events in individuals with DM and the Hp 2-2 genotype |
US20080213785A1 (en) * | 2000-04-20 | 2008-09-04 | Andrew Levy | Method of predicting a benefit of antioxidant therapy for prevention or treatment of vasclar disease in hyperglycemic individuals |
US20020037855A1 (en) * | 2000-05-05 | 2002-03-28 | Fritz Stanislaus | Stabilized medicament containing cysteinyl derivatives |
US6355666B1 (en) * | 2000-06-23 | 2002-03-12 | Medinox, Inc. | Protected forms of pharmacologically active agents and uses therefor |
US6429223B1 (en) * | 2000-06-23 | 2002-08-06 | Medinox, Inc. | Modified forms of pharmacologically active agents and uses therefor |
US6365176B1 (en) * | 2000-08-08 | 2002-04-02 | Functional Foods, Inc. | Nutritional supplement for patients with type 2 diabetes mellitus for lipodystrophy |
IT1319201B1 (it) * | 2000-10-12 | 2003-09-26 | Nicox Sa | Farmaci per il diabete. |
WO2002036202A2 (en) * | 2000-11-02 | 2002-05-10 | Nutrition 21, Inc. | Methods and compositions for the improvement of insulin sensitivity, reduction of hyperglycemia, and reduction of hypercholesterolemia with chromium complexes and alpha lipoic acid |
US6589948B1 (en) * | 2000-11-28 | 2003-07-08 | Eukarion, Inc. | Cyclic salen-metal compounds: reactive oxygen species scavengers useful as antioxidants in the treatment and prevention of diseases |
UA80393C2 (uk) * | 2000-12-07 | 2007-09-25 | Алтана Фарма Аг | Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці |
CA2427271A1 (en) * | 2000-12-14 | 2002-06-20 | Brigham And Women's Hospital, Inc. | Inflammatory markers for detection and prevention of diabetes mellitus |
US20030191064A1 (en) * | 2001-01-23 | 2003-10-09 | Kopke Richard D. | Methods for preventing and treating loss of balance function due to oxidative stress |
JP2002226457A (ja) * | 2001-02-02 | 2002-08-14 | Ajinomoto Co Inc | 新規シスチン誘導体及び炎症因子活性化抑制剤 |
US6566401B2 (en) * | 2001-03-30 | 2003-05-20 | The Board Of Trustees Of The Leland Stanford Junior University | N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity |
EA200301204A1 (ru) * | 2001-04-30 | 2004-04-29 | Тромсдорф ГмбХ унд Ко.КГ Арцнаймиттель | Фармацевтически активные производные нуклеозида, способ их получения, их применение (варианты) и содержащая их фармацевтическая композиция, способ профилактики и/или лечения заболеваний и нарушений млекопитающих (варианты), комбинация лекарственных средств и ее применение (варианты) |
US6669955B2 (en) * | 2001-08-28 | 2003-12-30 | Longwood Pharmaceutical Research, Inc. | Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin |
WO2003024426A1 (en) * | 2001-09-21 | 2003-03-27 | Egalet A/S | Controlled release solid dispersions |
US7670612B2 (en) * | 2002-04-10 | 2010-03-02 | Innercap Technologies, Inc. | Multi-phase, multi-compartment capsular delivery apparatus and methods for using same |
AU2003253887A1 (en) * | 2002-07-12 | 2004-02-02 | Atherogenics, Inc. | Novel salt forms of poorly soluble probucol esters and ethers |
US7148211B2 (en) * | 2002-09-18 | 2006-12-12 | Genzyme Corporation | Formulation for lipophilic agents |
JP4886297B2 (ja) * | 2002-11-01 | 2012-02-29 | バイオデリバリー サイエンシーズ インターナショナル インコーポレイティッド | ジオデート送達媒体 |
US8093292B2 (en) * | 2002-11-22 | 2012-01-10 | Bionexus, Ltd. | Methods for the treatment of HIV-1 related fat maldistribution, fasting hyperlipidemia and modification of adipocyte physiology |
US8017651B2 (en) * | 2002-11-22 | 2011-09-13 | Bionexus, Ltd. | Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia |
MXPA02012315A (es) * | 2002-12-13 | 2004-06-24 | Univ Autonoma Metropolitana | Compuesto farmaceutico que contiene silimarina y carbopol, su proceso de fabricacion y su uso como regenerador del tejido y celulas pancreaticas de secrecion endogena danados por diabetes mellitus. |
US20090036516A1 (en) * | 2003-01-13 | 2009-02-05 | Ctg Pharma S.R.L. | Compounds for treating metabolic syndrome |
WO2006066894A1 (en) * | 2004-12-24 | 2006-06-29 | Ctg Pharma S.R.L. | Compounds for treating metabolic syndrome |
WO2004082621A2 (en) * | 2003-03-15 | 2004-09-30 | Bethesda Pharmaceuticals, Inc. | Novel ppar agonists, pharmaceutical compositions and uses thereof |
US7981915B2 (en) * | 2003-04-30 | 2011-07-19 | Beth Israel Deaconess Medical Center | Methods for modulating PPAR biological activity for the treatment of diseases caused by mutations in the CFTR gene |
AT500404A1 (de) * | 2003-07-17 | 2005-12-15 | Jsw Res Forschungslabor Gmbh | Chemische verbindungen enthaltend tocopherol sowie zumindest einen weiteren pharmazeutischen wirkstoff |
US8173840B2 (en) * | 2003-07-29 | 2012-05-08 | Signature R&D Holdings, Llc | Compounds with high therapeutic index |
US20070254055A1 (en) * | 2003-11-21 | 2007-11-01 | Trustees Of Tufts College | Therapeutic Avenanthramide Compounds |
US7078064B2 (en) * | 2003-12-03 | 2006-07-18 | George Zabrecky | Compositions and methods useful for treating and preventing chronic liver disease, chronic HCV infection and non-alcoholic steatohepatitis |
US20050143356A1 (en) * | 2003-12-08 | 2005-06-30 | Vanderbilt University | Selective inhibition of cyclooxygenase 1 in the treatment of diabetic nephropathy |
EP1740196B1 (en) * | 2004-03-23 | 2015-08-26 | Lifeline Nutraceuticals Corporation | Compositions and method for alleviating inflammation and oxidative stress in a mammal |
WO2005112914A2 (en) * | 2004-04-20 | 2005-12-01 | Atherogenics, Inc. | Phenolic antioxidants for the treatment of disorders including arthritis, asthma and coronary artery disease |
WO2005115455A2 (en) * | 2004-05-17 | 2005-12-08 | Combinatorx, Incorporated | Methods and reagents for the treatment of immunoinflammatory disorders |
RU2007103178A (ru) * | 2004-06-30 | 2008-08-10 | Комбинаторкс, Инкорпорейтед (Us) | Способы и реагенты для лечения метаболических нарушений |
EP1796681A2 (en) * | 2004-08-02 | 2007-06-20 | Genmedica Therapeutics SL | Compounds for inhibiting copper-containing amine oxidases and uses thereof |
US8252321B2 (en) * | 2004-09-13 | 2012-08-28 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
US20080038316A1 (en) * | 2004-10-01 | 2008-02-14 | Wong Vernon G | Conveniently implantable sustained release drug compositions |
WO2006043671A1 (ja) * | 2004-10-22 | 2006-04-27 | Kirin Beer Kabushiki Kaisha | 転写因子Nrf2活性化剤およびその機能が付与された食品 |
US20060099279A1 (en) * | 2004-11-09 | 2006-05-11 | Council Of Scientific & Industrial Research | Novel anti-diabetic herbal formulation |
BRPI0520207A2 (pt) * | 2004-12-08 | 2012-09-25 | Revision Therapeutics Inc | uso de uma quantidade eficaz de um primeiro composto, e, medicamento sistemicamente formulado |
US20060166901A1 (en) * | 2005-01-03 | 2006-07-27 | Yu Ruey J | Compositions comprising O-acetylsalicyl derivatives of aminocarbohydrates and amino acids |
CA2595486A1 (en) * | 2005-01-20 | 2006-07-27 | Sirtris Pharmaceuticals, Inc. | Use of sirtuin-activating compounds for treating flushing and drug induced weight gain |
US20060172012A1 (en) * | 2005-01-28 | 2006-08-03 | Finley John W | Anti-inflammatory supplement compositions and regimens to reduce cardiovascular disease risks |
US20080033027A1 (en) * | 2005-03-21 | 2008-02-07 | Vicus Therapeutics Spe 1, Llc | Drug combination pharmaceutical compositions and methods for using them |
KR20080028357A (ko) * | 2005-04-21 | 2008-03-31 | 글렌 에이. 골드스타인 | 산화성 스트레스에 관련된 질병 및 증상 치료용n-아세틸시스테인 아미드(nac 아미드) |
US20060270635A1 (en) * | 2005-05-27 | 2006-11-30 | Wallace John L | Derivatives of 4- or 5-aminosalicylic acid |
US20070149466A1 (en) * | 2005-07-07 | 2007-06-28 | Michael Milburn | Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders |
US20090325975A1 (en) * | 2005-07-15 | 2009-12-31 | Helmut H Buschmann | Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain |
US8975227B2 (en) * | 2005-07-15 | 2015-03-10 | Emisphere Technologies, Inc. | Intraoral dosage forms of glucagon |
WO2007019417A1 (en) * | 2005-08-04 | 2007-02-15 | Sirtris Pharmaceuticals, Inc. | Oxazolopyridine derivatives as sirtuin modulators |
EP1960356A2 (en) * | 2005-11-03 | 2008-08-27 | Ilypsa, Inc. | Multivalent indole compounds and use thereof as phospholipase-a2 inhibitors |
CA2631713A1 (en) * | 2005-12-02 | 2007-09-13 | Sirtris Pharmaceuticals, Inc. | Modulators of cdc2-like kinases (clks) and methods of use thereof |
WO2007067570A1 (en) * | 2005-12-05 | 2007-06-14 | Biomarin Pharmaceutical Inc. | Methods and compositions for the treatment of disease |
EP2737897A3 (en) * | 2005-12-09 | 2014-10-01 | Metaproteomics, LLC | Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes |
US7814420B2 (en) * | 2005-12-14 | 2010-10-12 | Honeywell International Inc. | System and method for providing context sensitive help information |
JP2007176799A (ja) * | 2005-12-27 | 2007-07-12 | Sankyo Co Ltd | 置換ベンゼン化合物を含有する医薬 |
US20070231273A1 (en) * | 2006-03-31 | 2007-10-04 | Jie Wu | Method for Decreasing Blood Glucose Levels |
US20080015251A1 (en) * | 2006-04-10 | 2008-01-17 | Yissum Research Development Co., Of The Hebrew University Of Jerusalem | Means and method for treating lipotoxicity and other metabolically related phenomena |
US7629158B2 (en) * | 2006-06-16 | 2009-12-08 | The Procter & Gamble Company | Cleaning and/or treatment compositions |
US20080139525A1 (en) * | 2006-08-31 | 2008-06-12 | The Brigham And Women's Hospital, Inc. | Antioxidant therapies |
EP2069477A4 (en) * | 2006-10-06 | 2010-12-08 | Celtaxsys Inc | CHEMOREPULSION OF CELLS |
US7498048B2 (en) * | 2006-11-16 | 2009-03-03 | Jose Angel Olalde Rangel | Renal phyto-nutraceutical composition |
MX2009007720A (es) * | 2007-01-16 | 2013-03-22 | Ipintl Llc | Nueva composicion para el tratamiento del sindrome metabolico. |
US20090169497A1 (en) * | 2007-12-31 | 2009-07-02 | Horwitz Lawrence D | Treatment and Prevention of Skin Injury Due to Exposure to Ultraviolet Light |
JP2012520343A (ja) * | 2009-03-16 | 2012-09-06 | ジェンメディカ・セラピューティックス・ソシエダッド・リミターダ | 代謝障害治療のための併用療法 |
-
2009
- 2009-05-13 JP JP2011508909A patent/JP5669729B2/ja not_active Expired - Fee Related
- 2009-05-13 CN CN2009801273287A patent/CN102088965B/zh not_active Expired - Fee Related
- 2009-05-13 EP EP09745769A patent/EP2291182A1/en not_active Withdrawn
- 2009-05-13 US US12/465,201 patent/US20090298923A1/en not_active Abandoned
- 2009-05-13 CN CN2013101223642A patent/CN103251631A/zh active Pending
- 2009-05-13 CA CA2724023A patent/CA2724023C/en not_active Expired - Fee Related
- 2009-05-13 BR BRPI0912716A patent/BRPI0912716A2/pt not_active IP Right Cessation
- 2009-05-13 WO PCT/EP2009/055788 patent/WO2009138437A1/en active Application Filing
- 2009-05-13 AU AU2009248057A patent/AU2009248057B2/en not_active Ceased
-
2013
- 2013-03-14 US US13/829,266 patent/US20130281413A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN102088965A (zh) | 2011-06-08 |
CN102088965B (zh) | 2013-05-08 |
AU2009248057B2 (en) | 2013-02-21 |
CA2724023A1 (en) | 2009-11-19 |
EP2291182A1 (en) | 2011-03-09 |
CA2724023C (en) | 2014-02-18 |
WO2009138437A4 (en) | 2010-03-04 |
US20130281413A1 (en) | 2013-10-24 |
AU2009248057A1 (en) | 2009-11-19 |
JP2011520836A (ja) | 2011-07-21 |
US20090298923A1 (en) | 2009-12-03 |
BRPI0912716A2 (pt) | 2015-10-13 |
CN103251631A (zh) | 2013-08-21 |
WO2009138437A1 (en) | 2009-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5669729B2 (ja) | 代謝性障害を治療するのに有用なサリチレートコンジュゲート | |
US8575217B2 (en) | Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders | |
JP2012520343A (ja) | 代謝障害治療のための併用療法 | |
AU2005228685B2 (en) | Hydrazide-containing CFTR inhibitor compounds and uses thereof | |
CA2691446C (en) | Pro-drugs of nsaias with very high skin and membranes penetration rates and their new medicinal uses | |
EP2610242A1 (en) | Positively charged water-soluble prodrugs of aspirin | |
US7414139B2 (en) | Catalytic antioxidants and methods of use | |
JP2017165764A (ja) | 代謝異常を治療するのに有用な抗炎症剤及び抗酸化剤の抱合体を含む医薬配合物 | |
US8466197B2 (en) | Thiocarbonates as anti-inflammatory and antioxidant compounds useful for treating metabolic disorders | |
AU2013206215C9 (en) | Positively charged water-soluble prodrugs of aspirin | |
AU2013205946A1 (en) | Salicylate conjugates useful for treating metabolic disorders | |
WO2013037984A1 (en) | Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders | |
KR100983990B1 (ko) | Atp 시트르산 리아제의 발현 억제용 의약 조성물 | |
Karagiannis et al. | 3 Genetic and Epigenetic Basis of Myocardial Ischemia and Reperfusion Injury |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120510 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120510 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20131121 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140218 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140318 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140617 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140624 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140717 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20141118 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20141216 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5669729 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |